PhenoVista Biosciences Receives $250K Phase 1 SBIR Grant for Microglia Models for Alzheimer’s Disease drug screening

January 21, 2021 9:00 AM / by PhenoVista Biosciences

SAN DIEGO, Calif.– January 21, 2021 – PhenoVista Biosciences has been awarded $249,900 by the National Institutes of Health (NIH) National Institute for Aging (NIA) under the Small Business Innovative Research (SBIR) program to develop microglia models for Alzheimer’s disease (AD) drug screening. PhenoVista will use induced pluripotent stem cell-derived microglia (iMGLs) in a phenotypic assay to score the efficacies of AD microglia-based therapies, including the effects of compounds on microglial migration and phagocytosis induced by tau and amyloid-beta aggregates. These assays will also be adapted in co-culture with iPSC-derived neurons or primary rodent neurons to study the effects of various soluble factors, such as cytokines, to model neuroinflammation.

“Support from the NIH is crucial to our goal of creating and commercializing new techniques and strategies for studying difficult diseases. The development of this physiologically relevant phenotypic assay will provide a relatively low-cost, high-throughput, quantitative platform of a suite of iMGL/neuronal assays for assessing microglial therapeutic modulators. Once developed, these assays will be made available to biotech/pharmaceutical companies, academic researchers, and disease foundations to aid in screening for drug candidates and development of therapies for treating neurodegenerative diseases like Alzheimer’s,” said Dr. James Evans, CEO of PhenoVista.

PhenoVista’s core expertise is combining physiologically relevant 2D and 3D cell models and quantitative fluorescence imaging into phenotypic assays for drug discovery, medical device development, toxicity testing, and other applications. Support from the NIH is an important part of the company’s overall strategy to develop new assays for challenging diseases and commercialize them through partnerships. This research will be supported by the NIA of the NIH under Award Number 1R43AG071341-01.

About PhenoVista Biosciences

PhenoVista Biosciences is the leading provider of custom imaging-based phenotypic assay services. With a collaborative and scientifically driven project design and management approach, PhenoVista has a proven track record of delivering high quality data from robust and scalable assays. Phenovista’s key advantage lies in the ability of their industry-trained scientists to combine world-class understanding of diverse biological systems with cutting-edge quantitative imaging to deliver clear, actionable output data. For more information, please visit Follow PhenoVista on LinkedIn, Twitter, and Facebook.


Raymond Price, PhD
VP, Business Development
PhenoVista Biosciences, LLC.

Scroll to Top